A new combination of darovasertib and crizotinib shows remarkable promise for metastatic uveal melanoma (MUM), a historically hard-to-treat eye cancer. In the Phase 1/2 OptimUM-01 trial, patients receiving this therapy lived a median of 21.1 months—nearly double the usual survival—and went about seven months without disease progression, more than twice the expected duration. The treatment achieved a 34% objective response rate and a 90% disease control rate, far exceeding standard outcomes.
The therapy targets the GNAQ and GNA11 mutations present in most MUM tumors. Darovasertib blocks the PKC pathway that drives tumor growth, while crizotinib complements this by inhibiting related signaling, producing a synergistic anti-tumor effect.
The combination was well tolerated and delivered strong, durable responses, offering a potentially new standard of care for MUM by significantly extending survival and controlling disease where options have been limited.